Perfluorocarbon blood substitutes

Critical Reviews in Oncology and Hematology

Volumn 6, Issue 4, 1987, Pages 311-374

  Biro, George P ^a   Blais, Pierre ^b,c   Rosen, Arthur L ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HEALTH CANADA   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL BLOOD; FLUOROCARBON; FLUOSOL DA;

BIOLOGICAL MODEL; BLOOD AND HEMOPOIETIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; REVIEW; THERAPY;

BIOLOGICAL TRANSPORT; BLOOD SUBSTITUTES; CHEMISTRY; CHEMISTRY, PHYSICAL; DRUG ADMINISTRATION SCHEDULE; FLUOROCARBONS; GASES; HEMORRHAGE; HUMAN; INFUSIONS, PARENTERAL; ISCHEMIA; METABOLIC DETOXICATION, DRUG; NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0023131650     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(87)80018-5     Document Type: Article

References (244)

1. A review of the physics of critical point drying
2. The perfluorocarbon gases in the treatment of retinal detachment
3. Industrial polymers as implants—their value and their limitations
4. Biocompatibility of perfluorinated polymers and composites based on these polymers
5. Coagulation, hemostasis and plasma expanders: a quarter century enigma
6. Effect of plasma expanders on coagulation and hemostasis—dextran, hydroxyethyl starch and other macromolecules revisited
7. Properties of perfluorinated liquids
8. Fluid fluorocarbon as oxygenator in experimental extracorporeal circulation
9. Fluid fluorocarbon as an oxygenator in prolonged experimental extracorporeal circulation
10. Development of a liquid-liquid blood oxygenator
11. A liquid-liquid contactor for extracorporeal blood oxygenation
12. Fluorohydrocarbon liquid oxygenator
13. Perfusion of whole animals with perfluorinated liquid emulsions using the Clark bubble-defoam heart-lung machine
14. The physiological effects of fluorocarbon liquids in blood oxygenation
15. Gas exchange across a liquid-liquid interface
16. LIQUID-LIQUID OXYGENATION
17. Blood oxygenation by liquid membrane permeation
18. A new type of liquid oxygenator
19. An investigation of centrifugal fluorocarbon blood oxygenation
20. Recent developments in centrifugal fluorocarbon blood oxygenation
21. Survival of mammals breathing organic liquid equilibrated with oxygen at atmospheric pressure
22. Erythrocyte substitutes for perfusion of brain
23. Survival of rats having red cells totally replaced by emulsified fluorocarbons
24. Dispersed fluorochemicals as substitutes for erythrocytes in intact animals
25. Opening address
26. A chemical stand-in for blood
27. Premiers essais concluants du “sang artificiel”
28. Blood substitute passes its first test
29. Further studies on intake and retention of Fluosol-DA in RES in humans
30. Can fluorocarbon emulsions be used as artificial blood
31. Distribution of fluorocarbon liquids
32. Les fluorocarbones transporteurs de gaz dissous comme substituts du sang
33. Fluorocarbon emulsions help blood supply
34. Transfusion of blood and blood substitutes: indications, contraindications and risks
35. Blood transfusion today—artificial blood tomorrow
36. Sequential triple-valve replacement in a Jehovah's Witness
37. The solubility of oxygen in highly fluorinated liquids
38. Hildebrand theory for gas solubilities in liquids
39. The physiology of synthetic blood
40. The physiological effects of artificial blood made from inert organic oxygen solvents
41. Ring versus straight chain perfluorocarbon emulsion for perfusion media
42. Fluorocarbons: properties and syntheses
43. Emulsions of perfluorinated solvents for intravascular gas transport
44. The synthesis and biological screening of new and improved fluorocarbon compounds for use as artificial blood substitutes
45. Preparation and physiological evaluation of some fluorinated volatile anaesthetics
46. Synthesis and biological activity of perfluoroadamantane and some closely related compounds
47. Morphology and morphometry of the liver after infusion of perfluorochemical emulsions: an assessment of 19 selected compounds
48. Selection of 53 PFC substances for better stability of emulsion and improved artificial blood substitutes
49. Artificial blood substitutes based on perfluorochemicals
50. Perfluorocompounds as artificial erythrocyte
51. The design of artificial blood substitutes
52. Application of perfluorocarbon compounds as radioopaque agent
53. Efficacy and toxicity studies with radioopaque perfluorocarbon
54. Perfluorocarbon compounds as X-ray contrast media in the lung
55. Radioopaque applications of brominated fluorocarbon compounds in experimental animals and human subjects
56. 19F and dissolved oxygen
57. 19F spin-lattice relaxation rates of Fluosol-DA
58. Treatment of P388 leukemia in vivo with perfluoroctylbromide and radiation: a preliminary study
59. Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice
60. Tumor imaging with X-rays using macrophage uptake of radioopaque fluorocarbon emulsions
61. Discrimination among dispersion forces at the aqueous-fluorocarbon interface
62. Blood substitutes
63. Relation between particle size and solubility.
64. Diffusion coefficients of respiratory gases in a perfluorocarbon liquid
65. Artificial blood emulsifiers
66. Experimental evaluation of Pluronic F-68 as a method of diminishing systemic fat emboli resulting from prolonged cardiopulmonary bypass
67. A comparison of Pluronic F-68, low molecular weight dextran and saline as priming agents in the heart-lung apparatus, 1.
68. POLOXALKOL® (PLURONIC F-68)
69. Prolonged retention in the circulation of emulsified lipid-coated PFC
70. Perfluorochemical blood replacement preparations
71. Neohemocytes
72. Perfusion of the brain and other isolated organs with dispersed perfluoro compounds
73. Liposome disposition in vivo. III. Dose and vesicle side effects
74. Detergent-like properties of polyethyleneglycols in relation to model membranes
75. Whole animal perfusion with fluorocarbon dispersions
76. An improved perfluorodecalin emulsion
77. Perfluorocarbons having a short dwell time in the liver
78. A new look at the vapor pressure problem in red cell substitutes
79. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%) — an overview of clinical studies with 185 patients
80. DEHP in blood bags and medical plastics: their limitations
81. Interactions between drugs and plastic intravenous fluid bags II. Leaching of chemical from bags containing various solvent media
82. Interactions between drugs and plastic intravenous fluid bags. I. Sorbtion studies on 17 drugs
83. Phthalic ester-free PVC for medical use; Medidex
84. Intravenous infusion of cis-trans perfluorodecalin emulsions in the rhesus monkey
85. Organic fluorocompounds in human plasma: prevalence and characterization
86. Determination of the solubilities of gases in perfluorocarbon fluids
87. Determination of fluorocarbon in blood
88. A simple and ultrasensitive head-space gas chromatographic method for the assay of fluorocarbon propellant in blood
89. Gas chromatographic-mass spectrometry of fluorocarbons 11 and 12 in biologic specimens
90. Food and Drug Administration regulations and licensure
91. Current status of erythrocyte substitutes
92. Present status of clinical studies of Fluosol-DA (20%) in Japan
93. Fluosol-DA, 20%: an inadequate red cell substitute in acute anemia
94. Fluorocarbon perfusion medium applied to the isolated rat brain
95. Perfluorochemical emulsion and perfusion of isolated organs
96. Neural activities during replacement of blood with fluorocarbon emulsion
97. Perfusion of the cervical spinal cord in situ of adult rats using perfluorocarbon emulsion
98. Isolated cardiac muscle performance during fluorocarbon immersion and effects of metabolic blockade
99. Perfluorochemical perfusion of the isolated guinea pig heart
100. Isolated working rat heart perfusion with perfluorochemical emulsion Fluosol-43
101. Myoglobin function in the isolated fluorocarbon-perfused dog heart
102. Comparison of acute cardiovascular effects and oxygen-supply following haemodilution with dextran, stroma-free haemoglobin solution and fluorocarbon suspension
103. Effects of fluorocarbons with and without oxygen supplementation on cardiac hemodynamics and energetics
104. High oxygen extraction combined with extensive oxygen consumption in the rat liver perfused with Fluosol-DA, a new perfluoro compound emulsion
105. Secretion of insulin by the canine pancreas perfused ex vivo with flurocarbon emulsion
106. Simultaneous study of canine hepatic, gastric and pancreatic function in an isolated preparation perfused ex-vivo with fluorocarbon emulsion
107. Evaluation of hepatocellular and Kupffer cell function of the isolated guinea pig liver perfused by a fluorocarbon medium. I.
108. Studies on isolated rat liver perfused by perfluoro-compound emulsion
109. Electrical and mechanical activity of isolated canine stomach perfused with fluorocarbon emulsion
110. Improved sodium and PAH transport in the isolated fluorocarbon-perfused rat kidney
111. 2 histograms and other parameters in canine kidneys during perfusion with Oxypherol
112. Use of fluorochemicals for renal perfusion
113. Fluorochemical perfusates for renal preservation
114. Beneficial effect of fluorocarbon emulsion media on the function of neuromuscular preparations in vitro
115. Accelerated removal of platelets during perfusion of isolated lungs with perfluoro erythrocyte substitute
116. Effect of fluorocarbon emulsions on the mechanical fragility of normal and sickle cells: in vitro studies
117. Coagulation defects in rabbits after infusion of dispersed fluorochemicals
118. Effect of a perfluoro erythrocyte substitute on platelets in vitro and in vivo
119. Effects of perfluorochemical on phagocytic function of leukocytes
120. Effect of perfluorochemical blood substitutes on human neutrophil function
121. Paralysis of phagocyte migration due to an artificial blood substitute
122. Perfluorochemical blood substitutes differentially alter human monocyte procoagulant generation and oxidative metabolism
123. Immunological biocompatibility in blood substitutes
124. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis
125. Mixtures of artificial and whole blood
126. Effect of a nonionic surface-active agent on blood viscosity and platelet adhesiveness
127. Liquid-gas partition coefficients of halothane and isoflurane in perfluorodecalin, Fluosol-DA, and blood/Fluosol-DA mixtures
128. Interaction of oxygen-carrying resuscitation fluids with morphine. I
129. Recovery from pentobarbital-induced sleep after administration of perfluorinated blood substitutes
130. Substitutes for blood and its components
131. Perfluorochemical blood replacement preparations
132. PFC as blood substitutes—an overview
133. Surfactants and perfluorochemical emulsions for use in blood replacement preparations
134. A method for evaluation of blood substitutes in the conscious animal
135. Acute responses during blood substitution in the conscious rat
136. 2 levels during endotoxemia
137. Development of a perfluorochemical emulsion as a blood gas carrier
138. Anaemia and haemodilution
139. Red cell substitutes: hemoglobin solution or fluorocarbon?
140. Assessment of a 35% fluorocarbon emulsion
141. Oxygen toxicity
142. Maternal and fetal effects of exchange transfusion with a red blood cell substitute
143. Effects of a partial exchange transfusion with Fluosol-DA 20% on healthy pig
144. Perfluorochemicals: morphologic changes in infused liver, spleen, lung and kidney of rabbits
145. 19F NMR
146. Retention of perfluorochemicals in circulating blood and organs of animals after intravenous injection of their emulsions
147. Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships
148. Artificial blood
149. Blood and blood substitutes
150. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation
151. Long-term experiments of perfluorochemicals using rabbits
152. Long-term observation of PFC storage in organs of rats after various dosages
153. Fluosol 43 particle localization pattern in target organs of rats. An electron microscopy study
154. Variation in toxicity of Escherichia coli endotoxin after treatment with perfluorated blood substitutes in mice
155. Perfluorocarbon emulsions in cancer therapy: preliminary observations on presently available formulation
156. Potential application of perfluorochemicals in cancer therapy
157. Some long-term effects of exchange transfusion with fluorocarbon emulsion in Macaque monkey
158. Effect of perfluorochemicals on host defense, especially on the reticuloendothelial system
159. Effect of a perfluorocarbon emulsion (Fluosol-DA) on reticuloendothelial system clearance function
160. Clinical experience with Fluosoi-DA
161. Tolerance of an oxygen-carrying colloidal plasma: substitute in human being
162. Clinical studies of perfluorochemical whole blood substitutes: safety of Fluosol-DA (20%) in normal human vollunteers
163. 2 transport associated with the perfluorochemical blood substitute Fluosol-DA
164. U.S. clinical studies on the treatment of anemia with Fluosol-DA (20%)
165. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA): summary of 186 cases
166. Cardiovascular effect of various colloidal solutions during major abdominal surgery
167. Success in the radical resection of esophageal cancer with artificial blood infusion: case report
168. Hypotensive reaction after infusion of a perfluorochemical emulsion
169. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss
170. Effect of Fluosol-DA on, carbon monoxide poisoning in dogs
171. Perfluorochemical as a treatment of decompression sickness in rats
172. Fluorocarbons: a potential treatment of cerebral air embolism in open-heart surgery
173. Whole body oxygenation using intraperitoneal perfusion of fluorocarbons
174. Fluorocarbons in the resuscitation of hemorrhage
175. An evaluation of perfluorochemical resuscitation after hypoxic hypotension
176. The properties of Fluosol-DA infusion in the treatment of hemorrhagic shock
177. Fluorocarbons reduce myocardial ischemic damage after coronary occlusion
178. Fluorocarbon and dextran hemodilution in myocardial ischemia
179. Effect of fluorocarbon exchange transfusion on myocardial infarction size in dogs
180. Limitations of fluorocarbons in reducing myocardial infarction size
181. Effects of intravenous fluorocarbons during and without oxygen enhancement on acute myocardial ischemic injury assessed by intramyocardial gas tensions
182. Effect of perfluorochemical (Fluosol-DA) on infarct morphology in dogs
183. Treatment of postischemic reperfusion cardiac injury with a perfluorochemical solution
184. Reduction of infarction size with intracoronary perfluorochemical in a canine preparation of reperfusion
185. Fluosol-DA: an artificial blood for total cardiopulmonary bypass
186. Improved myocardial metabolism with oxygenated, perfluorocarbon cardioplegia
187. Maintenance of aerobic metabolism during global ischemia with perfluorocarbon cardioplegia improves myocardial preservation
188. Fluosol cardioplegia: a method for optimizing aerobic metabolism during arrest
189. Superiority of perfluorocarbon cardioplegia over blood and crystalloid cardioplegia
190. Extracorporeal circulation with perfluorochemicals (Fluosol-DA)
191. Metabolic enhancement of myocardial preservation during cardioplegic arrest
192. Protection of the hypertrophied pig myocardium
193. The use of perfluorochemicals during open heart surgery
194. Perfluorochemical emulsions for the treatment of cerebral ischemia
195. Experimental study of new cerebral protective substances: functional recovery of severe incomplete ischemic brain lesions pretreated with mannitol and fluorocarbon emulsion
196. Protective effect of Fluosol-DA in acute cerebral ischemia
197. The effect of Fluosol-DA on oxygen availability in focal cerebral ischemia
198. Modification of cerebral ischemia with Fluosol
199. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study
200. Clinical evaluation of artificial blood substitute (Fluosol-DA, 20%) in patients of cerebral ischemia
201. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). II. Human cerebral blood flow
202. Initial results of a trial of Fluosol-DA, 20% in acute cerebral ischemia
203. Prevention of brain tissue hypoxia by intrathecal injection of oxygenated fluorocarbon
204. Role of tissue hypoxia in local regulation of cerebral microcirculation
205. Severe cerebral ischemia treatment by ventriculosubarachnoid perfusion with an oxygenated fluorocarbon emulsion
206. Focal cerebral ischemia: reduction in size of infarcts by ventriculosubarachnoid perfusion with fluorocarbon emulsion
207. Oxygenated fluorocarbon perfusion as treatment of acute spinal cord compression injury in dogs
208. Oxygenated fluorocarbon nutrient solution in the treatment of experimental spinal cord injury
209. Intestinal ischemia: reduction of mortality utilizing intraluminal perfluorochemical
210. Limb preservation in replantation surgery
211. Effect of fluorocarbon perfusion upon the preservation of amputated limbs
212. Normothermic whole body rinse-out utilizing perfluorochemical-containing artificial blood
213. Retrieval of artificial blood cells (perfluorochemical) from whole blood
214. Diagnostic products
215. Nephrotoxicity associated with the use of radiological contrast drugs
216. Effects of synthetic blood combined with contrast medium on coronary endothelium: an experimental study
217. Renal dysfunction after arteriography
218. Intercurrent embolization during cerebral angiography; clinical and experimental observations
219. Discussion in Fluosol-DA: an artificial blood for total cardiopulmonary bypass
220. Discussion in Fluosol-DA: an artificial blood for total cardiopulmonary bypass
221. Imaging of complex NMR spectra
222. Perfluorochemical emulsion can increase tumor radiosensitivity
223. Experimental studies on the possible combined chemotherapy to neoplasms with Fluosol-DA infusion
224. Gaseous exchange and acid-base balance in premature lambs during liquid ventilation since birth
225. 2